Orthocell Share Price and Company Fundamentals



Price
$0.47
Change
-0.020 (-4.082%)
52 week
0.435 - 0.655

Last traded: Today at 4:57 AM

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia and internationally. The company's principal products include CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of tendons, peripheral nerves, bones, and articular cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation for the treatment of symptomatic defects of the articulating cartilage of the joints, primarily in the knee and ankle. In addition, the company develops Striate+ for use in bone and soft tissue repair; SMRT Graft for use in to augment repair of rotator cuff tendinopathy and tear; and Remplir, a nerve wrap. Orthocell Limited was incorporated in 2006 and is based in Murdoch, Australia.

Key Metrics

PE ratio

-

PB ratio

6.33

Dividend yield

Beta

0.07

Market cap

-

Enterprise value

-

Company profile

Primary activitiesRegenerative medicine sector for chronic degenerative diseases and injury.
Industry / SectorBiotechnology / Healthcare
Websitehttps://www.orthocell.com.au
Mailing addressBuilding 191 Murdoch University South Street Murdoch WA 6150 Australia
Phone / Fax61 8 9360 2888 / 61 8 9360 2899
Share registryAUTOMIC REGISTRY SERVICES

Dividends

Orthocell does not pay dividends.

Company Executives

As of Jan 2022, following are the company executives and directors listed on Orthocell.

NameTitleAgeTotal Pay
Dr. Stewart James Washer B.Sc., BSc (Hons), Ph.D.Exec. Chairman51150k
Mr. Paul Frederick AndersonCEO, MD & Exec. Director55522.23k
Ms. Leslie Wise J.D.Exec. Director66.34k
Ms. Nicole Jane TelfordChief Financial Officer
Mr. Alex McHenryChief Operating Officer
Prof. Ming Hao ZhengChief Scientific Officer and Member of Medical & Scientific Advisory Board
Mr. Simon Lee Robertson B.Bus, C.A., CA, M Appl. Fin.Company Sec.61

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

-1,142.59%

Return on assets

-34.21%

Return on equity

-47.84%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Orthocell is and its enterprise value is .

The OCC's stocks Beta value is 0.07 making it 93% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Orthocell (OCC)

Orthocell (ASX:OCC) Frequently Asked Questions

1. What is Orthocell's Stock Symbol?

Orthocell trades on ASX under the ticker symbol "OCC".

2. What is Orthocell's stock price today?

One share of OCC stock can currently be purchased for approximately $0.47.

3. How can I contact Orthocell?

Orthocell's mailing address is Building 191 Murdoch University South Street Murdoch WA 6150 Australia. The company can be reached via phone at 61 8 9360 2888.

4. What is Orthocell's official website?

The official website of Orthocell is https://www.orthocell.com.au.

5. Which share registry manages Orthocell's stock?

Orthocell's stock is managed by AUTOMIC REGISTRY SERVICES.